Study on achievement of target LDL-C in Dyslipidemic patients
Journal Title: International Journal of Research in Pharmacology & Pharmacotherapeutics (IJRPP) - Year 2013, Vol 2, Issue 1
Abstract
Cardiovascular diseases are the leading cause of illness and morbidity in developing and developed countries. The majority of cardiovascular cases stem from atherosclerosis and epidemiological studies have identified dyslipidemia is the prime etiology for the atherosclerosis. A prospective observational study was conducted at a multispecialty hospital in the General Medicine and Cardiology departments for a period of 8 months. The study was carried among 80 dyslipidemic patients. From the lipid profile data it was found that 15(18.75%) patients LDL-C found to be above optimum level, 5(6.25%) patients LDL-C found to be borderline high, majority of the patients 42(52.5%) were found to have high LDL-C levels and 18(22.5%) patients LDL-C was found to be very high. All the study population required drug therapy as per ATP III guidelines of NCEP. The majority of patients (95%) were receiving lipid lowering therapy with statins and rest of the patients was on combination therapy. The patients were categorized based on the risk factors, 40 (50%) as CHD group, 34 (42.5%) as high risk non CHD group and 6 (7.5%) belongs to low risk non CHD group. For the high risk non CHD group ten year risk percentage for having CHD was calculated and the results reveal that 3(8.8%) patients were found to have <10% of risk for CHD, 10(29.4%) patients has 10-20% of risk for CHD and 21(61.8%) patients have >20% of risk for CHD. Based on the risk groups assessment of target LDL-C was performed and the results reveals that 22.5% of study population achieved the target LDL-C described by ATP III guideline, which was found to be unsatisfactory. The study results necessitates the need for more aggressive management is required to attain target LDL-C levels. The pharmaceutical care can be the key for successive lipid lowering therapy.
Authors and Affiliations
V. Shivashankar V. Shivashankar
Keywords
Related Articles
- EP ID EP411875
- DOI -
- Views 133
- Downloads 0
Drug pricing of various formulations used for the management of acid peptic disorders
ntroduction Affordability determines accessibility to drugs in developing countries. Variation in the cost of drugs is noted to be high in India, which can affect drug compliance. Acid Peptic disorders are prevalent in...
Niosomes: An excellent tool for drug delivery
The ideal drug delivery system delivers drug at rate dictated by the need of the body over the period of treatment and it channels the active entity solely to the site of action. Niosomes are non-ionic surfactant vesicl...
CNS depressant activity of ethyl acetate leaf extract of Avicennia officinalis in mices
The present study deals with the investigation of the ethyl acetate extracts of Avicennia officinalis leaves was assessed for an effect on the central nervous system (CNS) using neuropharmacological experimental models (...
A review of orphan drugs and rare diseases
The World Health Organization defines orphan diseases, as all pathological conditions, affecting 0.65-1 out of every 1000 inhabitants. They are usually not studied for their path physiology or for newer therapeutic optio...
Translational Pharmacology: New approach of drug discovery
Increasingly, the field is recognizing the need to enable a closer collaboration of industry and academia to create a more efficient system for developing new drugs. In parallel with this, the world of drug discovery ha...